Cover Image
Market Research Report
Product code 
1111766

Colorectal Cancer Epidemiology Analysis and Forecast, 2021-2031

Published: | GlobalData | 53 Pages | Delivery time: 1-2 business days

Price

Back to Top
Colorectal Cancer Epidemiology Analysis and Forecast, 2021-2031
Published: June 29, 2022
GlobalData
Content info: 53 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Colorectal cancer (CRC) (ICD-10 = C18-C20), also referred as bowel cancer, is the cancer of the colon, rectum, or rectosigmoid junction. It is a type of gastrointestinal malignancy originating from either the colon or the rectum. CRC is the second most lethal cancer after lung cancer, and the third most diagnosed malignant tumor worldwide (World Health Organization, 2022). The disease usually begins as non-cancerous polyps on the inner lining of the colon or rectum. Over time some types of polyps can change into cancer (American Cancer Society, 2020).

Early cases of CRC are often asymptomatic, however, can be detected by screening. CRC symptoms depend on the size and location of the cancer. Some commonly experienced symptoms include changes in bowel habit, diarrhea or constipation, feeling of bowel not being empty properly, blood in feces, abdominal pain, bloating, fatigue or tiredness, unexplained weight loss, and anemia (American Cancer Society, 2022).

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CRC. The diagnosed incident cases of CRC are segmented by age (18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older) and sex. The diagnosed incident cases are further segmented by the AJCC stage at diagnosis (stage I, stage II, stage III, and stage IV), by recurrence of stages I-III into stage IV disease, and by molecular markers. The report also provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of CRC. The following data describes epidemiology of CRC. In the 8MM, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of CRC from 1,004,915 cases in 2021 to 1,317,175 cases in 2031, at an AGR of 3.11% over the forecast period. Men accounted for more diagnosed incident cases of CRC than women in the 8MM and it predominantly affects older adults. These findings are in line with the GlobalData estimates and these trends are reflected in GlobalData's forecast for the diagnosed incident cases for the 8MM.

Scope

The Colorectal Cancer (CRC) Epidemiology Report and Model provide an overview of the risk factors and global trends of CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China).

The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CRC. The diagnosed incident cases of CRC are segmented by age (18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older) and sex. The diagnosed incident cases are further segmented by the American Joint Committee on Cancer (AJCC) stage at diagnosis (stage I, stage II, stage III, and stage IV), by recurrence of stages I-III into stage IV disease, and by molecular markers. The report also provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of CRC.

The CRC epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The Colorectal Cancer Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CRC market.
  • Quantify patient populations in the global CRC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CRC therapeutics in each of the markets covered.
  • Understand magnitude of CRC population by stage at diagnosis, recurrence of stages I-III into stage IV disease, and molecular markers.
Product Code: GDHCER298-22

Table of Contents

Table of Contents

1 Colorectal Cancer: Executive Summary

  • 1.1 Catalyst
  • 1.2 Related Reports
  • 1.3 Upcoming Reports

2 Epidemiology

  • 2.1 Disease Background
  • 2.2 Risk Factors and Comorbidities
  • 2.3 Global and Historical Trends
  • 2.4 8MM Forecast Methodology
    • 2.4.1 Sources
    • 2.4.2 Forecast Assumptions and Methods
    • 2.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of CRC
    • 2.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of CRC by AJCC Stage at Diagnosis
    • 2.4.5 Forecast Assumptions and Methods: Diagnosed Incident Cases of CRC by Recurrence of Stages I-III into Stage IV Disease
    • 2.4.6 Forecast Assumptions and Methods: Diagnosed Incident Cases of CRC by Molecular Markers
    • 2.4.7 Forecast Assumptions and Methods: Five-Year Diagnosed Prevalent Cases of CRC
  • 2.5 Epidemiological Forecast for CRC (2021-31)
    • 2.5.1 Diagnosed Incident Cases of CRC
    • 2.5.2 Age-Specific Diagnosed Incident Cases of CRC
    • 2.5.3 Sex-Specific Diagnosed Incident Cases of CRC
    • 2.5.4 Diagnosed Incident Cases of CRC by AJCC Stage at Diagnosis
    • 2.5.5 Diagnosed Incident Cases of CRC by Recurrence of Stages I-III into Stage IV Disease
    • 2.5.6 Diagnosed Incident Cases of CRC by Molecular Markers
    • 2.5.7 Five-Year Diagnosed Prevalent Cases of CRC
  • 2.6 Discussion
    • 2.6.1 Epidemiological Forecast Insight
    • 2.6.2 COVID-19 Impact
    • 2.6.3 Limitations of the Analysis
    • 2.6.4 Strengths of the Analysis

3 Appendix

  • 3.1 Bibliography
  • 3.2 About the Authors
    • 3.2.1 Epidemiologist
    • 3.2.2 Reviewers
    • 3.2.3 Global Director of Therapy Analysis and Epidemiology
    • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • Contact Us

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbid Conditions Associated with CRC
  • Table 4: 8MM, Diagnosed Incident Cases of CRC by Molecular Markers, Both Sexes, Ages ≥18 Years, N, 2021

List of Figures

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of CRC, Both Sexes, N, Ages ≥18 Years, 2021 and 2031
  • Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of CRC, Both Sexes, N, Ages ≥18 Years, 2021 and 2031
  • Figure 3: 8MM, Diagnosed Incidence of CRC, Men, Cases Per 100,000 Population, Ages ≥18 Years, 2011-31
  • Figure 4: 8MM, Diagnosed Incidence of CRC, Women, Cases Per 100,000 Population, Ages ≥18 Years, 2011-31
  • Figure 5: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CRC
  • Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Stage at Diagnosis
  • Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Recurrence into Stage IV Disease
  • Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers (KRAS Mutation, NRAS Mutation, BRAF Mutation, BRAF V600E Mutation, and PIK3CA/PTEN Mutation)
  • Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers (MSI-H/dMMR Molecular Subtype, HER2 Amplification, MET Amplification, and NTRK Gene Fusion)
  • Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers (DPYD, High TMB, Elevated CEA, and UGT1A1 Mutation)
  • Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers (POLE Mutation, TP53 Mutation, APC Mutation, and PD-L1 Expression on Tumors)
  • Figure 12: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of CRC
  • Figure 13: 8MM, Diagnosed Incident Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2021
  • Figure 14: 8MM, Diagnosed Incident Cases of CRC by Age, N, Both Sexes, 2021
  • Figure 15: 8MM, Diagnosed Incident Cases of CRC by Sex, N, All Ages, 2021
  • Figure 16: 8MM, Diagnosed Incident Cases of CRC by AJCC Stage at Diagnosis, N, All Ages, 2021
  • Figure 17: 8MM, Diagnosed Incident Cases of CRC by Recurrence of Stages I-III into Stage IV Disease, N, Both Sexes, Ages ≥18 Years, 2021
  • Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2021